LENZ Therapeutics (LENZ) Return on Capital Employed (2021 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Return on Capital Employed of 44.93% for Q1 2026, down 1516.0% year-over-year from 3.17% in Q1 2025, and down 16.89% quarter-over-quarter from 38.44% in Q4 2025.
LENZ Therapeutics (LENZ) Return on Capital Employed (2021 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Return on Capital Employed for 6 consecutive years, with 44.93% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 1516.0% year-over-year to 44.93%; the TTM figure through Mar 2026 stood at 44.93% (down 1516.0% YoY), while the FY2025 annual figure was 38.07%, up 619.0% from the prior year.
- Return on Capital Employed fell to 44.93% in Q1 2026 per LENZ's latest filing, from 38.44% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 20.4% in Q1 2022 and bottomed at 60.74% in Q1 2024.
- Historically, Return on Capital Employed has averaged 34.18% across 5 years, with a median of 31.15% in 2025.
- Annual changes were most pronounced in 2024 — Return on Capital Employed slumped 3014 bps — and 2025, when it soared 3097 bps.
- LENZ Therapeutics' Return on Capital Employed stood at 33.5% in 2022, then tumbled by 44 bps to 48.35% in 2023, then jumped by 42 bps to 28.01% in 2024, then sank by 37 bps to 38.44% in 2025, then fell by 17 bps to 44.93% in 2026.
- Business Quant data shows LENZ's Return on Capital Employed at 44.93% in Q1 2026, 38.44% in Q4 2025, and 34.34% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.03 Bn | 131.18 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.93 Bn | 52.80 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.95 Bn | 36.86 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.00 Bn | 9.60 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 7.88% |
| 10 | LENZ Therapeutics | 147.46 Mn | 147.46 Mn | 5.21 Mn | -57.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -57.15% |
| Mar 31, 2026 | -44.93% |
| Dec 31, 2025 | -38.44% |
| Sep 30, 2025 | -34.34% |
| Jun 30, 2025 | -31.15% |
| Mar 31, 2025 | -29.77% |
| Dec 31, 2024 | -28.01% |
| Sep 30, 2024 | -33.25% |
| Jun 30, 2024 | -37.39% |
| Mar 31, 2024 | -60.74% |
| Dec 31, 2023 | -48.35% |
| Sep 30, 2023 | -28.09% |
| Jun 30, 2023 | -28.12% |
| Mar 31, 2023 | -30.60% |
| Dec 31, 2022 | -33.50% |
| Sep 30, 2022 | -29.57% |
| Jun 30, 2022 | -24.36% |
| Mar 31, 2022 | -20.40% |
| Dec 31, 2021 | -15.23% |
| Sep 30, 2021 | -12.76% |